Mustang Bio, Inc. (MBIO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Mustang Bio, Inc. (MBIO) closed at USD 0.37 on 2026-10-14, a change of -75.3 % over the past year, with a market capitalization of USD 2.93M.

Mustang Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Mustang Bio, Inc. key figures

Previous close

USD 0.37 (2026-10-14)

1-year change

-75.3 %

Market cap

USD 2.93M

Enterprise value

USD -12.22M

P/E ratio (trailing)

-0.86

P/E ratio (forward)

-1.10

EPS (trailing)

-0.45

EPS (forward)

-0.35

PEG ratio

n/a

Price to book

0.39

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.96

Employees

4

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Mustang Bio, Inc.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Mustang Bio, Inc. and compare it with other stocks.